|
業務類別
|
-- |
|
業務概覽
|
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically majority of the revenue is derived from Mainland China. |
| 公司地址
| No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051 |
| 電話號碼
| +86 57187772180 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.venusmedtech.com |
| 員工數量
| 691 |
| Mr. Liqiao Ma |
Executive Director and Vice President, Clinical Medicine |
-- |
29/04/2024 |
| Ms. Meirong Liu |
Director and Vice President |
-- |
29/04/2024 |
| Mr. Hou-Sen Lin Haosheng Lim |
Executive Director and General Manager |
-- |
29/04/2024 |
|
|
| Mr. Zhang Ao |
Director |
29/04/2024 |
| Mr. Ting Yuk Anthony Wu |
Independent Director |
29/04/2024 |
| Mr. Chi Wai Suen |
Independent Director |
29/04/2024 |
| Mr. Liqiao Ma |
Executive Director and Vice President, Clinical Medicine |
29/04/2024 |
| Mr. Wei Wang |
Director |
29/04/2024 |
| Ms. Meirong Liu |
Director and Vice President |
29/04/2024 |
| Mr. Hou-Sen Lin Haosheng Lim |
Executive Director and General Manager |
29/04/2024 |
|
|
|
|
